Tacrolimus Oral
Total Payments
$532,855
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $532,855 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $532,855 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Molecular markers to differentiate calcineurin inhibitor toxicity from immunological mechanisms associated with progression to kidney dysfunction in kidney transplant recipients | Astellas Pharma Global Development | $199,500 | 0 |
| Long-term Deterioration of Kidney Allograft Function (DeKAF) | Astellas Pharma Global Development | $168,006 | 0 |
| Financial burden of CMV mismatch (CMV Donor +/Recipient -) in lung transplant recipients. | Astellas Pharma Global Development | $72,000 | 0 |
| Tacrolimus adjustment by NFAT-related gene expression in lung allograft recipients (TANGELA) | Astellas Pharma Global Development | $58,188 | 0 |
| NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients | Astellas Pharma Global Development | $35,161 | 0 |
Top Doctors Receiving Payments for Tacrolimus Oral
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $532,855 | 5 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $532,855
Product Information
- Type Drug
- Total Payments $532,855
- Total Doctors 0
- Transactions 5
About Tacrolimus Oral
Tacrolimus Oral is a drug associated with $532,855 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $532,855 was paid across 5 transactions to 0 doctors.
The most common payment nature for Tacrolimus Oral is "Unspecified" ($532,855, 100.0% of total).
Tacrolimus Oral is associated with 5 research studies, including "Molecular markers to differentiate calcineurin inhibitor toxicity from immunological mechanisms associated with progression to kidney dysfunction in kidney transplant recipients" ($199,500).